{"disease":{"id":"hypochondroplasia","name":"hypochondroplasia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06212947","title":"A Multicenter Multinational Observational Study of Children With Hypochondroplasia","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT05328050","title":"Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT07393373","title":"Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":135,"lead_sponsor_name":"QED Therapeutics, a BridgeBio company","has_results":false},{"nct_id":"NCT06455059","title":"Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT07126262","title":"A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT01111019","title":"Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}